Smith ScholarWorks
Exercise and Sport Studies: Faculty
Publications

Exercise and Sport Studies

2007

Cerebral Hemodynamics After Short- and Long-Term Reduction in
Blood Pressure in Mild and Moderate Hypertension
Rong Zhanf
Presbyterian Hospital of Dallas

Sarah Witkowski
switkowski@smith.edu

Qi Fu
Jurgen A.H.R. Claassen
Benjamin D. Levine

Follow this and additional works at: https://scholarworks.smith.edu/ess_facpubs
Part of the Exercise Science Commons, and the Sports Studies Commons

Recommended Citation
Zhanf, Rong; Witkowski, Sarah; Fu, Qi; Claassen, Jurgen A.H.R.; and Levine, Benjamin D., "Cerebral
Hemodynamics After Short- and Long-Term Reduction in Blood Pressure in Mild and Moderate
Hypertension" (2007). Exercise and Sport Studies: Faculty Publications, Smith College, Northampton, MA.
https://scholarworks.smith.edu/ess_facpubs/41

This Article has been accepted for inclusion in Exercise and Sport Studies: Faculty Publications by an authorized
administrator of Smith ScholarWorks. For more information, please contact scholarworks@smith.edu

Cerebral Circulation in Hypertension
Cerebral Hemodynamics After Short- and Long-Term
Reduction in Blood Pressure in Mild and
Moderate Hypertension
Rong Zhang, Sarah Witkowski, Qi Fu, Jurgen A.H.R. Claassen, Benjamin D. Levine
Abstract—This study tested the hypothesis that acute reduction in blood pressure (BP) at the initial stage of
antihypertensive therapy compromises brain perfusion and dynamic cerebral autoregulation in patients with hypertension. Cerebral blood flow velocity and BP were measured in patients with mild and moderate hypertension and in
healthy volunteers at baseline upon reduction of BP within 1 to 2 weeks of administration of losartan/hydrochlorothiazide and after 3 to 4 months of treatment. The transfer function between beat-to-beat changes in BP and cerebral blood
flow velocity was estimated to assess dynamic autoregulation. After 1 to 2 weeks of treatment, BP was reduced in mild
(143⫾7/88⫾4 versus 126⫾12/77⫾6 mm Hg) and moderate hypertension (163⫾11/101⫾9 versus 134⫾17/
84⫾9 mm Hg; P⬍0.05). These reductions in BP were well maintained over the 3 to 4 month period. Cerebral blood flow
velocity did not change, whereas cerebrovascular resistance index was reduced by 17% (P⬍0.05) after reduction in BP.
Responses of cerebral blood flow velocity to head-up tilt remained unchanged. Baseline transfer function gain at the low
frequencies (0.07 to 0.20 Hz) was reduced in moderate hypertension, consistent with cerebral vasoconstriction and/or
enhanced dynamic autoregulation. However, this reduced transfer function gain was restored to the level of control
subjects after reduction in BP. These findings, contrary to our hypothesis, demonstrate that there is a rapid adaptation
of the cerebral vasculature to protect the brain from hypoperfusion even at the initial stage of antihypertensive therapy
in patients with mild and moderate hypertension. (Hypertension. 2007;49:1149-1155.)
Key Words: hemodynamics 䡲 brain 䡲 hypertension 䡲 cerebral blood flow 䡲 angiotensin AT1 receptor
䡲 transcranial Doppler
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T

he relationship between high blood pressure (BP) and the
risk of stroke and other cerebral and cardiovascular
diseases has been well established. Recent studies and the
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure also suggest the significant benefits of control of
systolic BP ⬍120 mm Hg and diastolic BP ⬍80 mm Hg in
the general population.1
However, despite these widely accepted guidelines, reduction in BP acutely and aggressively in patients with hypertension still is an important concern in clinical practice.2 For
the most part, these concerns are derived from the prevailing
concept that cerebral autoregulation is impaired in patients
with hypertension (ie, there is a rightward shift of the
steady-state cerebral autoregulatory curve to higher BPs).
Thus, brain hypoperfusion and ischemic damage may occur
associated with an acute and aggressive reduction in BP.3
In addition, accumulating evidence indicates that regulation of cerebral blood flow (CBF) under steady-state conditions may be related to, but not necessarily equivalent to, that

under dynamic conditions.4 – 6 In contrast to static autoregulation, which describes CBF responses to steady-state
changes in BP, dynamic autoregulation examines CBF responses to transient changes in BP in time scales of seconds
to minutes, which may be critical in preserving CBF during
rapid perturbations in BP presented in daily life.4,6
Recently, several studies have shown that dynamic autoregulation is likely to be preserved in patients with mild to
moderate hypertension5,7,8 but becomes less effective in
severe hypertension.9 However, one important question yet to
be answered is whether dynamic autoregulation is altered at
the initial stages of lowering of BP consequent to effective
antihypertensive treatment.
This study tested the hypothesis that, in contrast to the
salutary effects of long-term antihypertensive treatment
through vascular remodeling, brain perfusion and dynamic
autoregulation are compromised in patients with hypertension
after acute reduction in BP. For this purpose, changes in CBF
velocity in the middle cerebral artery, presumably reflective
of CBF, were measured before and after short- and long-term
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reduction in BP. Hypertension was treated with administration of a combination of angiotensin II type 1 (AT1) receptor
antagonist losartan with hydrochlorothiazide.10 Tests were
performed in the supine position and during head-up tilt
(HUT), because regulation of CBF is likely to be challenged
substantially under orthostatic stress.

this time period, arm BP also was measured. Then, subjects were
tilted up to a 70° position for 10 minutes. After 2 minutes for
stabilization, 6 minutes of continuous data and arm BP were
measured. Cardiac output and blood samples were obtained at the
end of HUT followed by returning the subjects back to the supine
position for recovery.

Methods

After the baseline test, patients were treated with low-dose losartan/
hydrochlorothiazide (50/12.5 mg once daily) for 1 week. The dose
was increased to 100/25 mg if the reduction in BP was not below a
previously determined level of systolic pressure ⬍140 mm Hg and
diastolic pressure ⬍90 mm Hg.1 In 1 patient with mild hypertension
who did not respond well to losartan/hydrochlorothiazide, a combination of calcium channel blocker (amlodipine, 10 mg) and hydrochlorothiazide (25 mg) was used to reduce BP. Data obtained from
this individual were similar to other patients and, thus, were pooled
together for statistical analysis. On reaching the goal of BP control
(within 1 to 2 weeks), testing (short-term) was repeated. Treatment
was continued for 3 to 4 months, and then testing (long-term) was
repeated again. In patients, 24-hour ambulatory BP (Accutracker II,
SunTech) was measured before treatment and repeated on the days
before the short- and long-term tests. In healthy subjects, 24-hour BP
was measured once at baseline and once before the long-term test.
The patients took their losartan/hydrochlorothiazide in the morning 2
to 3 hours before the study to ensure its optimal BP reduction
effects.10

Subjects
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Twelve patients with mild hypertension (3 women; racial makeup: 7
white, 3 black, 1 Hispanic, and 1 mixed race) with a mean age of
49⫾11 years (range: 27 to 66 years), 9 with moderate hypertension
(2 women; racial makeup: 4 white, 4 black, and 1 Hispanic) with a
mean age of 47⫾12 years (range: 36 to 62 years), and 9 healthy
subjects (2 women; racial makeup: 6 white and 3 black) with a mean
age of 46⫾11 years (range: 32 to 66 years) participated in this study.
All of the patients had newly diagnosed essential hypertension and
had not been treated with any antihypertensive medicine before the
study. Classification of mild (stage 1) and moderate hypertension
(stage 2) was based on the average of awake 24-hour ambulatory
BP.1 All of the subjects underwent a thorough medical history and a
physical examination, including a regular blood chemistry and
echocardiography to exclude the presence of other severe cardiovascular or cerebrovascular disease. For safety concerns, patients with
severe hypertension (systolic pressure ⬎180 mm Hg or diastolic
pressure ⬎110 mm Hg) were not included. The study was approved
by the institutional review boards of the University of Texas
Southwestern Medical Center and Presbyterian Hospital of Dallas.
One patient with moderate hypertension was lost to follow-up, and 1
patient with mild hypertension developed intolerable adverse effects
(sore throat) with low-dose losartan/hydrochlorothiazide and resigned from the study. Therefore, these subjects were not included in
the final data analysis of this study.

Instrumentation
Finger photoplethysmography (Finapres, Ohmeda) was used to
measure beat-to-beat changes in BP. The BP transducer was positioned carefully at the heart level in the supine position and during
70° HUT. Intermittent cuff BP was measured at the upper arm using
electrosphygmomanometry (SunTech). Cardiac output was measured with a modified acetylene rebreathing method. CBF velocity
was recorded in the middle cerebral artery (MCA) using transcranial
Doppler (Multiflow, DWL). The Doppler probe was placed over the
subject’s temporal window and fixed at a constant angle with a probe
holder that was custom made to fit each subject’s facial bone
structure. This technique allowed CBF velocity to be measured
precisely at the same acoustic window and at the same angle for
repeated studies.11 Heart rate was monitored using ECG. End-tidal
CO2 was monitored via a nasal cannula using a capnograph (Criticare
Systems Inc). Blood samples were drawn from the antecubital vein
in the supine position and at the end of HUT. Plasma norepinephrine
was measured by high-performance liquid chromatography (ARUP
Laboratories). Plasma renin activity and aldosterone were measured
using radioimmunoassay (ARUP Laboratories). Hematocrit was
measured using a microcentrifuge. Plasma volume was measured in
8 patients with mild and 1 with moderate hypertension using Evans
blue dye.12 This measurement was not available for the control
subjects, because the manufacturer terminated the Evans blue dye
production before the completion of this study.

Protocol
All of the experiments were performed in the morning ⱖ2 hours after
a light breakfast. The subjects refrained from heavy exercise and
caffeinated or alcoholic beverages at least 24 hours before the tests.
After ⱖ30 minutes of supine rest, blood samples were drawn, and
cardiac output was measured. Then, 6 minutes of beat-to-beat BP and
CBF velocity were measured during spontaneous breathing. During

Antihypertensive Treatment

Data Analysis
Steady-state BP was obtained from the average of ⱖ3 measurements
of arm BP during the 6-minute data collection periods. Steady-state
heart rate and CBF velocity were obtained from the average of
beat-to-beat data and end-tidal CO2 from the breath-to-breath data.
Total peripheral vascular resistance was estimated as mean BP
divided by cardiac output. Cerebrovascular resistance index (CVRI)
was calculated as mean BP divided by mean CBF velocity. During
HUT, hydrostatic effects of gravity on cerebral perfusion pressure
under steady-state conditions were not considered, because gravitational potential energy of blood is likely to be conserved in a closed
circulatory system.13
The magnitude of beat-to-beat changes in mean BP and CBF
velocity was quantified by power spectral analysis. Transfer function
and coherence function between these variables was calculated to
assess dynamic cerebral autoregulation as described previously
(Figure 1).6 In addition, normalized transfer function gain was
derived as the estimated transfer function gain times CVRI to
quantify relative changes in CBF velocity in response to relative
changes in BP.14 Because dynamic autoregulation most likely is
effective at low frequencies, and estimation of coherence function
was high (⬎0.5) at these frequencies,4 – 6,15 spectral power of BP and
CBF velocity and mean values of transfer function gain, phase, and
coherence were calculated in the low frequency range of 0.07 to 0.20
Hz in this study.

Statistics
Two-way repeated-measures ANOVA was used to compare the differences and interactions between the subject groups and the effects of
antihypertensive treatment, as well as HUT, on the steady-state
hemodynamics and spectral and transfer function analysis of BP
and CBF velocity. The Holm–Sidak method was used for posthoc
multiple comparisons if significant group and/or interaction
effects were detected (SigmaStat 3.11, Systat Software). Data are
presented as mean⫾SD. A value of P⬍0.05 was considered
statistically significant.

Results
Antihypertensive Treatment
Both 24-hour ambulatory BP and mean BP measured under
supine resting conditions and during HUT were reduced
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Figure 1. Group-averaged transfer function gain, phase, and coherence function
in the supine position and during HUT
before treatment. Solid line, control subject; dotted line, mild hypertension;
dashed line, moderate hypertension.
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significantly within 1 to 2 weeks of treatment (Tables 1 and
2). The magnitude of reduction in BP while awake was
similar to that during sleep (Table 1). However, heart rate did
not change after reduction in BP, suggestive of baroreflex
resetting (Tables 1 and 2). Reductions in BP were well
maintained over the period of 3 to 4 months with the same
dose of drugs used in each patient to reduce BP acutely. As
expected, plasma renin activity increased significantly after a
reduction in BP in moderate hypertension. However, plasma
volume did not change (baseline: 41⫾5 mL/kg, acute: 41⫾6
mL/kg, chronic: 44⫾5 mL/kg), consistent with the observation of no change in hematocrit (Table 1).

Steady-State Hemodynamics
Before treatment, no differences in CBF velocity and
cardiac output were observed between control subjects and
patients with hypertension (Table 2). However, CVRI and
total peripheral vascular resistance were increased significantly in moderate hypertension, suggesting both cerebral
and systemic vasoconstriction. After short- and long-term
reductions in BP, CBF velocity and cardiac output did not
change, whereas CVRI and total peripheral vascular resistance decreased in patients with hypertension (Table 2).
During HUT, when compared with the supine position,
CBF velocity, cardiac output, and end-tidal CO2 all were

TABLE 1. Measurement of 24-Hour BP and Heart Rate, Supine Plasma Renin Activity, Aldosterone, and Hematocrit Before and After
Short- and Long-Term Treatment
Baseline

1 to 2 Weeks

Variables

Control

Mild

Moderate

Age, y

46⫾11

49⫾11

47⫾12

175⫾12

177⫾11

Height, cm
Weight, kg

82⫾19

92⫾18

3 to 4 Months

Control

Mild

Moderate

䡠䡠䡠

126⫾12†

134⫾17†
84⫾9†

Control

Mild

Moderate

124⫾7

123⫾8†

129⫾12†

76⫾7

77⫾7†

79⫾9†

174⫾8
86⫾21

SBP awake, mm Hg

120⫾7

143⫾7*

163⫾11*

DBP awake, mm Hg

74⫾6

88⫾4*

101⫾9*

䡠䡠䡠

77⫾6†

SBP sleep, mm Hg

109⫾9

121⫾9*

148⫾13*

䡠䡠䡠

112⫾9†

120⫾12†

111⫾14

109⫾11†

115⫾12†

DBP sleep, mm Hg

66⫾9

74⫾6*

87⫾9*

䡠䡠䡠

68⫾6

76⫾8†

65⫾10

69⫾4

68⫾12†

HR awake, bpm

72⫾8

77⫾9

78⫾9

䡠䡠䡠

80⫾10

79⫾10

72⫾8

80⫾10

78⫾10

HR sleep, bpm

66⫾7

67⫾11

69⫾11

70⫾9

78⫾12

68⫾8

71⫾11

73⫾15

PRA, ng/mL/h

0.8⫾0.5

0.9⫾1.0

0.5⫾0.4

0.6⫾0.4

2.5⫾3.1

9.1⫾11.2*†

0.8⫾0.6

2.2⫾2.4

5.4⫾6.0†

Aldosterone, ng/dL

4.3⫾2.0

6.2⫾3.6

5.9⫾3.8

3.6⫾2.2

5.5⫾3.1

6.5⫾3.5

5.4⫾3.9

4.6⫾2.0

8.5⫾7.8

Hct, %

42⫾2

43⫾5

43⫾2

42⫾2

42⫾5

44⫾3

41⫾3

41⫾5

41⫾3

Data are mean⫾SD, n⫽9 for control, n⫽12 for mild, and n⫽9 for moderate hypertension. SBP indicates systolic blood pressure; DBP, diastolic blood pressure,
HR, heart rate; PRA, plasma renin activity; Hct, hematocrit.
*P⬍0.05 comparisons between control subjects and patients with hypertension under same treatment conditions.
†P⬍0.05 comparisons between baseline and treatment for the same group subjects.
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TABLE 2. Systemic and Cerebral Hemodynamics Under Supine Resting Conditions and During HUT Before and After Short- and
Long-Term Treatment
Baseline
Variables

Control

Mild

59⫾6

MBP, mm Hg
CO, L/min

1 to 2 Weeks

3 to 4 Months

Moderate

Control

Mild

Moderate

Control

70⫾9*

60⫾8

Mild

Moderate

67⫾12

69⫾7

59⫾6

67⫾9

87⫾10

100⫾10*

112⫾14*

88⫾10

88⫾4†

98⫾9*†

89⫾12

87⫾7†

93⫾9†

7.4⫾2.0

6.6⫾1.4

6.6⫾1.6

6.9⫾2.2

6.4⫾1.3

6.4⫾1.2

7.3⫾2.4

6.8⫾1.3

7.0⫾1.8

Resting
HR, bpm

TPR, dyne s cm⫺5

64⫾8

65⫾10

1011⫾283

1256⫾249

1456⫾491*

1115⫾346

1154⫾297

1277⫾264

1087⫾426

1056⫾210

1136⫾356†

CBFV, cm/s

55⫾12

58⫾15

50⫾8

58⫾16

61⫾14

55⫾11

56⫾13

60⫾14

54⫾9

CVRi mm Hg/cm/s

1.6⫾0.4

1.8⫾0.4

2.3⫾0.5*

1.6⫾0.4

1.5⫾0.3†

1.9⫾0.5†

1.7⫾0.4

1.5⫾0.3†

1.8⫾0.4†

ETCO2, mm Hg

37⫾3

37⫾4

36⫾5

36⫾5

36⫾5

37⫾4

38⫾6

35⫾5

35⫾5

NE, pg/mL

213⫾74

277⫾151

259⫾92

221⫾110

328⫾129

370⫾137

169⫾46

278⫾102

329⫾168

N GainLF

1.5⫾0.3

1.5⫾0.2

1.3⫾0.4

1.5⫾0.4

1.5⫾0.3

1.5⫾0.3

1.5⫾0.4

1.4⫾0.2

1.4⫾0.5

CohLF

0.5⫾0.2

0.7⫾0.1

0.6⫾0.2

0.5⫾0.1

0.7⫾0.1*

0.6⫾0.2

0.5⫾0.2

0.7⫾0.1*

0.6⫾0.2

HUT
HR, bpm

75⫾9‡

MBP, mm Hg

97⫾10‡

CO, L/min
TPR, dyne s cm⫺5

6.2⫾1.8‡
1348⫾401

81⫾9‡

75⫾8‡

88⫾12*‡

87⫾15‡

73⫾10‡

82⫾10‡

79⫾16‡

104⫾13

86⫾13‡

126⫾13*‡

99⫾11‡

97⫾12†‡

104⫾15†

95⫾10‡

95⫾15†‡

102⫾7†‡

4.8⫾1.4‡

5.4⫾1.7‡

6.0⫾2.3‡

5.2⫾1.5‡

5.3⫾1.0‡

6.3⫾1.9‡

6.0⫾1.4†‡

6.1⫾1.4‡

1870⫾538‡ 2158⫾1208*‡ 1457⫾447‡ 1643⫾547‡ 1599⫾420†‡ 1289⫾281

1346⫾429†‡ 1423⫾460†‡

CBFV, cm/s

50⫾11‡

49⫾15‡

45⫾6‡

51⫾10‡

53⫾16‡

48⫾10‡

52⫾16

52⫾14‡

46⫾6‡

CVRi mm Hg/cm/s

2.1⫾0.7‡

2.2⫾0.6‡

2.9⫾0.5*‡

2.0⫾0.5‡

1.9⫾0.5‡

2.3⫾0.7†‡

2.0⫾0.7‡

1.9⫾0.4†‡

2.3⫾0.4†‡

34⫾4‡

33⫾4‡

NE, pg/mL

558⫾304‡

590⫾242‡

483⫾111‡

530⫾284‡

684⫾209‡

720⫾303†‡

388⫾109‡

555⫾177‡

557⫾152‡

N GainLF

1.8⫾0.6‡

1.8⫾0.3‡

1.4⫾0.3

1.7⫾0.4

1.8⫾0.4

1.5⫾0.3

1.7⫾0.4

1.6⫾0.3‡

1.6⫾0.3

CohLF

0.7⫾0.2

0.7⫾0.2

0.6⫾0.2

0.5⫾0.2

0.8⫾0.2

0.7⫾0.2

0.6⫾0.2

0.6⫾0.2

0.6⫾0.1

ETCO2, mm Hg

35⫾5

34⫾5

33⫾5‡

34⫾4

34⫾6‡

33⫾6

32⫾5
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Data are mean⫾SD, n⫽9 for control, n⫽12 for mild, n⫽9 for moderate hypertension. HR indicates heart rate; MBP, mean blood pressure; CO, cardiac output;
TPR, total peripheral vascular resistance; CBFV, cerebral blood flow velocity in the middle cerebral artery; CVRi, cerebrovascular resistance index (MBP/CBFV); NE,
plasma norepinephrine; N GainLF, normalized transfer function gain at the low frequencies; CohLF, coherence function at the low frequencies.
*P⬍0.05 comparisons between control subjects and patients with hypertension under the same treatment and postural conditions.
†P⬍0.05 comparisons between baseline and treatment for the same group of subjects and under the same postural conditions.
‡P⬍0.05 comparisons between supine and HUT for the same group subjects and under the same treatment conditions.

reduced, whereas heart rate, mean BP, total peripheral vascular resistance, CVRI, and plasma norepinephrine were
increased (Table 2). However, these typical systemic and
cerebrovascular responses to orthostatic stress were similar
between control subjects and patients with hypertension and
persisted after both short- and long-term reduction in BP. Of
note, similar to the supine position, when compared with
baseline, CVRI during HUT was reduced significantly after
reduction in BP (Table 2).

During HUT, when compared with the supine position,
transfer function gain did not change, whereas phase was
reduced and normalized transfer function gain increased in
control subjects and in mild hypertension before treatment.
However, these changes were not altered after reduction in
BP (Figure 3 and Table 2). Estimation of coherence function
at the low frequencies was ⱖ0.5 under all of the experimental
conditions (Table 2).

Transfer Function Gain and Phase

The main findings of this study are threefold. First, CBF
velocity did not change after short- and long-term reduction
in BP in patients with mild and moderate hypertension.
Second, during HUT, CBF velocity and cardiac output were
reduced similarly in control subjects and in patients with
hypertension. However, both systemic and cerebral hemodynamic responses to HUT were not altered after reduction in
BP. Third, transfer function gain between beat-to-beat
changes in BP and CBF velocity was reduced significantly in
patients with moderate hypertension, a pattern typically
associated with improved rather than impaired dynamic
autoregulation. However, this reduced transfer function gain

BP and CBF velocity variability in the supine position and
during HUT at baseline and after reduction in BP are shown
in Figure 2. Before treatment, when compared with control
subjects, transfer function gain at the low frequencies was
reduced significantly in patients with moderate hypertension
(Figures 1 and 3). However, this reduced transfer function
gain was restored to the level of control subjects after shortand long-term reduction in BP (Figure 3). Estimation of phase
and normalized transfer function gain did not change in
patients with hypertension and were not altered after reduction in BP (Figure 3 and Table 2).

Discussion
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Figure 2. Changes in spectral power of
mean blood pressure (MBP) and CBF
velocity (CBFV) variability in the supine
position and during HUT at baseline and
after short- and long-term reduction in BP
at the low frequencies of 0.07 to 0.20 Hz.
Data are mean⫾SD, n⫽9 for control (C,
solid line), n⫽12 for mild (dotted line), and
n⫽9 for moderate hypertension (Mo,
dashed line). * P⬍0.05, comparisons
between control subjects and patients
with moderate hypertension. †P⬍0.05,
comparisons between baseline and longterm treatment in moderate hypertension.
‡P⬍0.05 comparisons between the supine
position and HUT.

was restored to the level of control subjects after reduction in
BP, associated with a reduction in cerebrovascular resistance.
Collectively, these findings, contrary to our hypothesis,
indicate that, when compared with control subjects, brain
perfusion and dynamic autoregulation are not compromised
in patients with mild and moderate hypertension and are not
compromised after either short- or long-term reduction in BP.

CBF Under Steady-State Conditions
Downloaded from http://ahajournals.org by on May 10, 2022

When compared with age- and sex-matched normotensive
subjects, similar or reduced CBF was observed in patients
with hypertension.3 This study extends these previous observations by showing that steady-state CBF velocity and,
presumably, CBF did not change in patients with mild and
moderate hypertension and remained unchanged after shortand long-term reduction in BP. Several mechanisms may lead
to these observations. First, it is likely that, although there
might be a rightward shift of the steady-state cerebral
autoregulatory curve to higher BPs in hypertension and these
changes may impair CBF responses to hypotensive stimuli,3
the magnitude of reduction in BP in this study may still be

within the autoregulatory pressure range. Thus, CBF would
remain unchanged. However, because the magnitude of
reductions in BP while awake was similar to that during sleep
(Table 1), it is unknown whether CBF still would remain
unchanged for these additional reductions in BP at night,
which may fall below the lower limit of autoregulation and,
thus, may lead to silent brain ischemia.16
Second, the rightward shift of the cerebral autoregulatory
curve in hypertension may be normalized acutely (within 1 to
2 week) with administration of AT1 receptor antagonist (ie, a
leftward shift of the curve).17 In addition, AT1 receptor
blockade, per se, may cause cerebral vasodilation.18 However, it is not clear whether losartan would pass the blood–
brain barrier in humans. If this was the case, CBF also would
remain unchanged after reduction in BP. Regardless of the
specific mechanisms, the fact that CBF velocity was stable
after short-term reduction in BP suggests that there is a rapid
adaptation of the cerebral vasculature to protect the brain
from hypoperfusion. In contrast, a preserved CBF after
long-term antihypertensive therapy most likely is associated
with cerebrovascular remodeling.3,19

Figure 3. Changes in transfer function
gain and phase in the supine position and
during HUT at baseline and after shortand long-term reduction in BP at the low
frequencies of 0.07 to 0.20 Hz. Data are
mean⫾SD, n⫽9 for control (C, solid line),
n⫽12 for mild (dotted line), and n⫽9 for
moderate hypertension (Mo, dashed line).
*P⬍0.05, comparisons between control
subjects and patients with moderate
hypertension. †P⬍0.05, comparisons
between baseline and short- and longterm reduction in BP in moderate hypertension. ‡P⬍0.05 comparisons between
the supine position and HUT.

1154

Hypertension

May 2007

Dynamic Autoregulation

Downloaded from http://ahajournals.org by on May 10, 2022

Several studies have shown that dynamic cerebral autoregulation was not altered in mild and moderate hypertension5,7,8
but became less effective in severe hypertension.9 In addition,
treatment of hypertension in the elderly for 6 months increased CBF velocity and carotid artery distensibility but did
not alter dynamic autoregulation assessed during transient
changes in BP.19
In the present study, transfer function gain at the low
frequencies was reduced in patients with moderate hypertension. These findings are consistent with previous studies
suggesting that dynamic autoregulation may be enhanced in
patients with moderate hypertension.5,7 That is, changes in
CBF velocity in response to spontaneous oscillations in BP
were attenuated in these patients. The new findings of this
study are that this reduced transfer function gain increased
and was restored to the level of control subjects after
reduction in BP.
The specific vascular mechanisms responsible for these
observations cannot be determined in this study. However,
we speculate that changes in transfer function gain observed
in patients with moderate hypertension could be related to
changes in cerebrovascular resistance estimated under steadystate conditions. Theoretically, an enhanced cerebrovascular
resistance would attenuate CBF responses to changes in
arterial pressure not only under steady state but also under
dynamic conditions (in analogy to the effect of changes in
Ohm’s resistance in a circuit on oscillations in current in
response to oscillations in electrical potentials).20 Consistent
with this hypothesis, reduction in transfer function gain in
moderate hypertension before treatment is likely to be induced by cerebral vasoconstriction and an enhanced cerebrovascular resistance, whereas increases in transfer function
gain after treatment are likely to be induced by cerebral
vasodilation and decreases in cerebrovascular resistance.
During HUT, estimation of phase was reduced, whereas
normalized transfer function gain was increased in control
subjects and in mild hypertension. These data suggest that
dynamic autoregulation, when quantified by the phase relationship or relative changes in CBF velocity in response to
relative changes in BP, becomes less effective under orthostatic stress.9,21 Interestingly, these changes were not observed in patients with moderate hypertension before treatment in accordance with the argument that dynamic
autoregulation may be enhanced in these patients.5,7

Vascular Reactivity During HUT
In this study, reductions in cardiac output, CBF velocity, and
end-tidal CO2 and increases in systemic and cerebrovascular
resistance during HUT were similar between control subjects
and patients with hypertension. In addition, these systemic
and cerebrovascular responses during HUT were not altered
after either short or long-term reduction in BP. Because
sympathetic activation during HUT is likely to be similar
between normotensive subjects and patients with hypertension,22 these findings suggest that systemic and cerebral
vascular reactivity to sympathetic neural or CO2 stimuli were
not altered in patients with hypertension and remained unchanged after antihypertensive treatment. However, whether

age and sex differences would affect these observations needs
to be determined in future studies.23

Study Limitations
Several methodologic limitations should be discussed. First,
the number of subjects in this study is relatively small.
Therefore, small changes in CBF velocity after reduction in
BP may not be detectable. However, the observation of stable
or slightly increased CBF velocity after treatment suggest that
BP lowering, if anything, may have increased rather than
decreased blood flow (Table 2). This possibility needs to be
tested in large-scale clinical trials.
Second, changes in CBF were assessed indirectly by the
measurement of CBF velocity in the MCA using transcranial
Doppler. Changes in CBF velocity reflect changes in blood
flow only if the insonated MCA diameter remains constant.
Several studies have demonstrated that there are no significant changes in the MCA diameters under moderate changes
in BP or end-tidal CO2.24 However, we cannot exclude the
possibility that vasodilation of the MCA may have occurred
after BP reduction. If this was the case, CBF would have been
increased in patients with hypertension as discussed above.
However, this possibility will strengthen rather than weaken
the conclusion of the present study. Relevant to this discussion, special caution also should be taken when comparing
cerebrovascular resistance based on the estimates of CVRI
between control subjects and patients with hypertension.
Such comparisons may not be valid if MCA diameters were
different between the subject groups. For these reasons, it is
the longitudinal relative changes in CVRI within each patient
group after reduction in BP, rather than the absolute values of
CVRI, that should be emphasized to reflect changes in
cerebrovascular resistance.
Third, changes in mean BP measured at heart level were
used to estimate changes in cerebral perfusion pressure both
in the supine position and during HUT. This estimation is
based on the assumption that intracranial and cerebral venous
pressures are relatively low and constant and that, during
HUT, hydrostatic components of intracranial and cerebral
venous pressure at head level are reduced commensurate with
arterial pressure for a closed circulatory system.13 However,
controversies regarding these assumptions must be recognized.25 Currently, there are no experimental data that either
unequivocally support or disprove this theory.26 Thus, for this
study, changes in cerebral hemodynamics in the same body
position after reduction in BP or the comparisons made
between the subject groups in response to HUT should be
emphasized, because changes in cerebral arterial or venous
hydrostatic pressure during HUT, whether or not commensurate, should be similar among subjects with a similar height
(Table 1).

Perspectives
Hypertension has been widely recognized as one of the
important risk factors in stroke, development of dementia,
and other cerebral and cardiovascular diseases. In this study,
we found that steady-state CBF velocity and dynamic cerebral autoregulation were not compromised in patients with
mild and moderate hypertension after short- or long-term

Zhang et al
reduction in BP with administration of losartan/hydrochlorothiazide. These findings support a clinical strategy of lowering of BP rapidly in middle-aged patients with mild and
moderate hypertension without fear of compromising brain
perfusion and dynamic autoregulation. Future studies are
warranted to determine the effects of antihypertensive therapy on cerebral hemodynamics in patients with severe hypertension, especially in the elderly. It is likely that aging, in
combination with hypertension, may cause cerebrovascular
damage and, thus, lead to a deterioration of cerebrovascular
function under these conditions.
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